Best Life Sciences Companies in New Hampshire, United States
The 67 best Life Sciences companies in New Hampshire, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Conformal Medical.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in New Hampshire
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Conformal Medical Innovating stroke prevention with minimally invasive Left Atrial Appendage Occlusion 50Funding top 20%Talent top 22%Growth top 26%Moat top 31% All 9 signals ▾Fundingtop 20% Talenttop 22% Growthtop 26% Moattop 31% Producttop 36% Newsbottom 45% Marketbottom 33% Globalbottom 32% Techbottom 24% Funding: Raised $129M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Talent: Analyst team rating 5/5 · 3 named leaders on record rank vs industry peers · Fliar Intelligence Index 50/100 | $129M | 10 mo ago | 29 29 → 57 (+97%) | Aaron Kaplan Founder and Chairman | Craft CMSPHPYii+10 | Top 10M | — | — |
| 2 | Salient Surgical Technologies Electrosurgical systems | $121M | 196 mo ago | — | Geoffery Martha CEO | — | — | 101 patents Fluid‑assisted electrosurgical devices and integrated fluid delivery/control systems for surgery | — |
| 3 | WaveForm Diabetes Provider of wearable sensors for glucose monitoring solutions | $56M | 83 mo ago | 87 | — | — | — | — | — |
| 4 | Lantos Provider of 3D digital ear canal scanners | $54M | 54 mo ago | 26 | — | — | — | 12 patents Medical cavity scanning and fluorescent imaging with fluid handling and fiducial markers | — |
| 5 | Celdara Medical Developer of therapeutics for the treatment of multiple diseases 21Funding top 30%Talent bottom 49%Tech bottom 38%Global bottom 32% All 6 signals ▾Fundingtop 30% Talentbottom 49% Techbottom 38% Globalbottom 32% Marketbottom 28% Newsbottom 22% Funding: Raised $46.5M across 37 rounds · 37 rounds over 17 yrs (2.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 21/100 | $46M | 12 mo ago | 16 16 → 19 (+19%) | Jake Reder CEO | — | — | — | — |
| 6 | Avitide Affinity purification solutions provider for biopharmaceutical manufacturing, improving purity, yield… | $37M | 80 mo ago | 34 | — | — | — | 44 patents Affinity ligands for viral capsid purification and gene‑therapy vector capture | — |
| 7 | Adimab Antibody discovery and optimization platform for autoimmune and infectious diseases | $35M | 170 mo ago | 121 121 → 139 (+15%) | Errik Anderson Co-Founder | WordPressApple iCloud MailMicrosoft 365+29 | Top 10M | 496 patents Engineered synthetic antibody libraries for therapeutic antibody discovery targeting CD3/CD28. | 1 partnership |
| 8 | Pristine Surgical Developer of single use digital imaging platform | $33M | 51 mo ago | 24 | Bryan Lord President & Chief Executive Officer | — | — | 18 patents Disposable and bendable endoscopic shafts with integrated imaging and injection for minimally invasive surgery | 1 launch |
| 9 | ImmuNext Biotech company developing immune-based, protein-based therapeutics for immune-related disorders | $24M | 60 mo ago | 13 | — | — | — | 141 patents Immuno‑oncology antibodies and steroid‑linked antibody‑drug conjugates for checkpoint inhibition | — |
| 10 | Boston Therapeutics Online slot game demo offering thrilling experiences and potential wins | $19M | 59 mo ago | 1 | — | — | — | — | — |
| 11 | GlycoFi Developer of yeast expression technology | $18M | 270 mo ago | 56 | Frank Schilling Founder | — | — | 328 patents Engineering yeast to produce human-like glycoproteins with tailored N‑glycan structures | — |
| 12 | Synedgen Restoring mucosal barrier function with first-in-class regenerative therapeutics | $14M | 16 mo ago | 8 | Shenda Baker Co-Founder | — | — | 185 patents Pharmaceutical formulations for wound healing, radioprotection, and biofilm‑disrupting chitosan agents | — |
| 13 | Occulo Developer of immunotherapies for the treatment of various diseases | $13M | 103 mo ago | — | Karl Griswold Co-Founder & CEO | — | — | — | — |
| 14 | Autem Therapeutics Developer of bioelectric technology-based device for cancer | $12M | 27 mo ago | 10 | Frederico Costa Co-Founder | — | — | — | — |
| 15 | VentriFlo Developing pulsatile blood pumps for superior cardiopulmonary support and improved patient outcomes | $10M | 81 mo ago | 13 13 → 10 (-23%) | — | — | — | 25 patents Provides pulsatile fluid pump technology for cardiovascular support and hemodynamic simulation. | — |
| 16 | Aponia Laboratories Developer of topical treatment for muscle soreness | $10M | 26 mo ago | 1 | Robert Boolbol Co-Founder | — | — | 31 patents Transdermal ibuprofen drug delivery systems for topical pain relief | — |
| 17 | CairnSurgical Developer of 3D printed surgical guides for breast cancer treatment | $8M | 22 mo ago | — | Venkat Krishnaswamy Co-Founder and Chief Technology Officer | — | — | 18 patents Surgical guidance and imaging support devices for precise tissue removal procedures | — |
| 18 | Vallum Corporation Spinal interbody fusion devices and pedicle screws systems | $6M | 102 mo ago | — | Stephen M Blinn CEO | — | — | — | — |
| 19 | Amcombi bioscience Specialty biotech company focused on developing vaccines | $4M | 74 mo ago | 5 | Charles Jones Co-Founder | — | — | — | — |
| 20 | Kantum Pharma Developer of therapies for treating acute kidney injury | $4M | 59 mo ago | — | Sylvie Breton Founder | — | — | — | — |
| 21 | Bio-AI Health AI-based disease diagnosis tool for healthcare professionals | $4M | 26 mo ago | 7 | Alan Jerusalmi Chief Innovation Officer & Co-founder | WordPressMySQLPHP+24 | Top 50M | — | — |
| 22 | Equipois Develops innovative exoskeleton technologies | $3M | 217 mo ago | 8 | Russ Angold Co-Founder of Ekso Bionics | — | — | 5 patents Robotic assistive devices and multi‑axis positioning mechanisms | — |
| 23 | Woomera Therapeutics Developing monoclonal antibody against multiple targets associated with the production and use of vasopressin… | $2M | 164 mo ago | — | Roy Pang CEO & CSO | — | — | — | — |
| 24 | M2S Real-world data solutions to improve patient outcomes and device performance | $2M | 162 mo ago | 84 | Wael Elseaidy CEO | Oracle Application ExpressApache HTTP ServerjQuery UI+7 | Top 50M | 24 patents Aggregating and analyzing clinical and radiologic data via a healthcare data marketplace platform. | — |
| 25 | Saureus Developer of point-of-care device to detect pathogens | $1M | 135 mo ago | — | George Newcomb Co-Founder & CEO | — | — | 7 patents Rapid diagnostic assays for detecting bacterial pathogens and toxins, e.g., C. difficile. | — |
| 26 | Lodestone Biomedical Provider of magnetic nanoparticle platform technology for in vivo biomarker monitoring in immuno-oncology | $1M | 11 mo ago | 5 | Lidia Valdes Co-Founder & CEO | — | — | — | — |
| 27 | Triterpenoid Therapeutics Developer of therapeutic solutions for the treatment of multiple health disorders | $930K | 69 mo ago | — | Michael B Sporn Founder | — | — | — | — |
| 28 | Aclys Developer of precision biologics for the treatment of cancer | $623K | 47 mo ago | 5 | Tony Cooper Co-Founder and CEO | — | — | — | — |
| 29 | PRO Therapeutics Developer of regenerative medicine for orthopedic diseases | $477K | 6 mo ago | — | Julie Lenzer CEO | — | — | — | — |
| 30 | ImmuRx Provider of toll-like receptor (TLR) and CD40 agonists for the treatment of cancer and infectious disease | $350K | 171 mo ago | — | David DeLucia CEO | — | — | 21 patents Synergistic immunotherapy adjuvants combining NKT activators with CD40 agonists. | — |
| 31 | Metabolic Solutions Hydrogen Breath Tests and Stable Isotope Analysis Service | $102K | 190 mo ago | 9 | Stephen Benoit CEO | Cart FunctionalityWooCommerceWordPress+40 | Top 10M | 112 patents Magnetic compression devices for gastrointestinal anastomosis and organ sealing | 1 partnership |
Top 12 Life Sciences companies in New Hampshire
#1
Series D · Nashua, New Hampshire · founded 2016 · 29 employees$129Mraised▾
Innovating stroke prevention with minimally invasive Left Atrial Appendage Occlusion. This company focuses on addressing the clinical need for improved stroke prevention in patients with Atrial Fibrillation (Afib). The company is developing a system for Left Atrial Appendage Occlusion (LAAO) as an alternative to blood thinners, aiming to reduce stroke risk without increased bleeding risk. Their solution targets a single-operator, same-day procedure performed under conscious sedation, eliminating the need for transesophageal echocardiography (TEE). This medical device company is dedicated to transforming LAAO procedures, offering a minimally invasive solution for stroke prevention. They are committed to advancing patient care through innovative medical technology.
- Jul 2025Series D$32M
- May 2023Series D$35M
- Aug 2020Series C$85M
- Dec 2018Series B$9M
#2
Funding Raised · Lebanon, New Hampshire · founded 2008 · 16 employees$46.5Mraised▾
Developer of therapeutics for the treatment of multiple diseases. The company is developing therapeutic antibodies, polymeric prodrugs, and cell therapies for the treatment of infectious diseases, rare diseases, and oncology indications.
- Jun 2025Grant (prize money)$653.1K
- Mar 2025Grant (prize money)$2.9M
- Feb 2025Grant (prize money)$2.3M
- Jan 2025Grant (prize money)$285.7K
#3
Series A · Claremont, New Hampshire · founded 2009 · 8 employees$14.1Mraised▾
Restoring mucosal barrier function with first-in-class regenerative therapeutics. This medical technology company develops life-saving products and therapies that encourage healing and reduce complications of tissue damage and inflammation. They focus on preventing infection by drug-resistant bacteria and removing biofilms. Their lead asset is an orally delivered therapeutic that repairs gastrointestinal mucosal injury, restoring function and reducing inflammation. They utilize glycopolymers to improve patient outcomes by promoting barrier function to repair mucosal injury. They offer targeted therapies with scalable GMP production, excellent safety profiles, and a strong IP position. Their therapeutics have demonstrated efficacy across multiple modalities. This is a B2B company in the biotechnology research industry.
- Feb 2025Grant (prize money)$4.4M
- Oct 2020Grant (prize money)—
- Jan 2020Grant (prize money)$2.6M
- Jun 2019Series A$2.5M
#4
Funding Raised · Manchester, New Hampshire · founded 2023$476.7Kraised▾
Developer of regenerative medicine for orthopedic diseases. It offers a platform for development of rotator cuff graft for soft tissue repair, allowing regeneration for tendons, ligaments, and muscles to restore native mechanical function.
- Dec 2025Grant (prize money)$238.4K
- Jan 2025Grant (prize money)$238.4K
#5
Seed · Hanover, New Hampshire · founded 2015 · 5 employees$1.1Mraised▾
Provider of magnetic nanoparticle platform technology for in vivo biomarker monitoring in immuno-oncology. Company's Immunotherapy Response Indication System (IRIS) interrogates the binding states of functionalized magnetic nanoparticles (fMNPs) localized in needle-implantable biosensor probes for real-time monitoring of signals of efficacy and treatment response within the tumor-immune microenvironment (TIME).
- Jun 2025Seed$75K
- Dec 2021Seed$450K
- Apr 2020Seed$110K
- Jul 2017Seed$550K
#6
Series A · Lebanon, New Hampshire · founded 2015$7.8Mraised▾
Developer of 3D printed surgical guides for breast cancer treatment. The company's proprietary Breast Cancer Locator System is a 3D-printed surgical guide to reduce positive margins during breast cancer tumor removal. It uses Visualizer to provide information regarding tumor size, shape, and margin boundary to assist surgeons in the excision of cancer and preserve normal breast tissue.
- Aug 2024Series A$4.5M
- Aug 2020Grant (prize money)$2M
- Dec 2019Series A$3.3M
- Sep 2018Grant (prize money)$2.2M
#7
Series A · Hampton, New Hampshire · founded 2010 · 1 employees$9.6Mraised▾
Developer of topical treatment for muscle soreness. The company offers pain relief product based on ibuprofen applications and a unique molecular bifurcation of the active ingredient, which has led to a more efficient and safer product. The topical pain relief product is still in development.
- Apr 2024Conventional Debt$507.5K
- Oct 2021Series A$35K
- Mar 2015Series A$1.2M
- Oct 2014Series A$1.5M
#8
Series A · Hanover, New Hampshire · founded 2022 · 10 employees$11.5Mraised▾
Developer of bioelectric technology and oncology therapeutics. It is developing a bioelectric platform AutEMsys that delivers personalized, amplitude-modulated electromagnetic (EM) frequencies for the treatment of hepatocellular carcinoma and other solid tumor cancers.
- Feb 2024Series A$1.5M
- Jun 2022Series A$10M
#9
Deadpooled · Derry, New Hampshire · founded 2009 · 26 employees$53.7Mraised▾
Provider of 3D digital ear canal scanners. It offers an intra-aural 3D scanner using emission re-absorption laser induced florence technology for mapping the human ear canal. It aims to eliminate the uncertainties associated with manual fits and offers a precise custom fit to the ear canal dimensions and brings a natural fit experience to custom made audio devices such as hearing aids,earphones, and noise canceling devices.
- Dec 2021Series B$1.5M
- Mar 2021Series B$3.9M
- Oct 2019Series B$5.2M
- Mar 2019Series B$12.6M
#10
Seed · Goffstown, New Hampshire · founded 2020 · 7 employees$3.5Mraised▾
AI-based disease diagnosis tool for healthcare professionals. The company has developed software that assists with precision medicine and patient profiling. It has features for pathology and multi-omic data analysis and diagnosis tool.
- Apr 2024Seed$500K
- May 2022Seed$3M
#11
Series D · Manchester, New Hampshire · founded 2011 · 24 employees$33Mraised▾
Pristine Surgical has developed a rigid endoscopy for single-use digital imaging. The Pristine Surgical Single-Use Digital Imaging Platform is sued for arthroscopic and laparoscopic procedures. It is a minimally invasive surgical tool and connected to the Pristine’s digital health services platform for recording the images.
- Mar 2022Series D$15M
- Mar 2020Series C$18M
#12
Funding Raised · Lebanon, New Hampshire · founded 2009 · 13 employees$24.4Mraised▾
ImmuneNext is a Biotech company developing immune-based, protein-based therapeutics for immune-related disorders. Their lead program, Anti-VISTA, is a negative checkpoint regulator antagonist for the treatment of cancer. ImmuneNext partnered with Janssen Biotech in Sep 2012 (potential payment of upto USD 150 M) for the development of Anti-VISTA, which is currently in Phase I. In May 2016 ImmuNext received USD 1,800,000 Award for pre-clinical development of Anti-CD40L for Lupus and other autoimmune diseases.
- Jun 2021Grant (prize money)$3M
- Mar 2018Grant (prize money)$3.3M
- Aug 2017Grant (prize money)$3.3M
- May 2016Grant (prize money)$1.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.